FibroBiologics Inc. (NASDAQ:FBLG – Free Report) – HC Wainwright raised their Q3 2026 earnings estimates for shares of FibroBiologics in a report issued on Tuesday, August 4th. HC Wainwright also issued estimates for FibroBiologics’ Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.89) EPS and FY2030 earnings at ($4.23) EPS. Weiss Ratings raised FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. FibroBiologics Company Profile(Get Free Report)FibroBiologics, Inc operates as a cell therapy, regenerative medicine company.